Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 7/20 | 0.79 |
| ▸ | HPGDS | O60760 | 5/20 | 0.67 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.64 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764022 | 0.88 | ESRRG (1.00) | ESRRGACKR3ESR1HDAC1HDAC3 | |
| SCHEMBL20764216 | 0.86 | ESRRG (0.69) | ESRRGHPGDSACKR3ESR1ESR2 | |
| SCHEMBL31687485 | 0.82 | ACKR3 (0.67) | ESRRGHPGDSACKR3ESR1ESR2 | |
| SCHEMBL20764262 | 0.82 | ESRRG (0.78) | ESRRGACKR3ESR1HDAC1HDAC3 | |
| SCHEMBL4930312 | 0.82 | ESRRG (0.74) | ESRRGACKR3HDAC1HDAC3HDAC4 | |
| SCHEMBL31337398 | 0.80 | NPC1 (0.81) | ESRRGHPGDSHSD17B1HSD17B2ESR1 | |
| SCHEMBL12496876 | 0.80 | HSD17B1 (0.65) | ESRRGHPGDSACKR3HSD17B1HSD17B2 | |
| SCHEMBL20764251 | 0.79 | ESRRG (0.73) | ESRRGHPGDSACKR3HDAC1HDAC3 | |
| SCHEMBL12057090 | 0.79 | ESRRG (0.65) | ESRRGHPGDSACKR3HDAC1 | |
| SCHEMBL25910317 | 0.79 | ESRRG (0.65) | ESRRGACKR3HDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795162-B2 | Modulators of the estrogen-related receptor | SAINT LOUIS UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200247792-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019036562-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247792-A1 | ERR INVERSE AGONISTS | ESRRA, ESRRB, ESR2 | ESRRG 4/4885HPGDS 1408/4885ACKR3 195/4885 |
| US-11795162-B2 | Modulators of the estrogen-related receptor | ESR2, GPER1, ESRRG | ESRRG 3/4885HPGDS 731/4885ACKR3 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.